U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H14N2O2
Molecular Weight 194.2307
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLRIAMFETOL

SMILES

c1ccc(cc1)C[C@]([H])(COC(=N)O)N

InChI

InChIKey=UCTRAOBQFUDCSR-SECBINFHSA-N
InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1

HIDE SMILES / InChI
Molecular Formula C10H14N2O2
Molecular Weight 194.2307
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

ADX-N05, originally discovered by SK Holdings, is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). ADX-N05 (Solriamfetol, sold under the brand name Sunosi) is approved in the US and is under regulatory review in the EU to improve wakefulness in adult patients with hypersomnia associated with narcolepsy or obstructive sleep apnoea.The US FDA has approved solriamfetol (Sunosi, Jazz Pharmaceuticals) for the treatment of excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.

Originator

Approval Year

2019
336
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7728
 2.9 µM [IC50]
Inhibitor
7728
 4.4 µM [IC50]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
499 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30865315/
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLRIAMFETOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5273 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30865315/
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLRIAMFETOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.6 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30865315/
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLRIAMFETOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Other AEs: Decreased appetite, Insomnia...
Other AEs:
Decreased appetite (9%)
Insomnia (5%)
Anxiety (6%)
Headache (16%)
Palpitations (2%)
Nausea (7%)
Dry mouth (4%)
Constipation (3%)
Agitation (<2%)
Bruxism (<2%)
Irritability (<2%)
Cough (<2%)
Hyperhidrosis (<2%)
Feeling jittery (<2%)
Thirst (<2%)
Chest discomfort (<2%)
Chest pain (<2%)
Weight decreased (<2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Disc. AE: Anxiety, Palpitations...
Other AEs: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Anxiety (0.5%)
Palpitations (0.5%)
Restlessness (0.5%)
Other AEs:
Headache (13%)
Nausea (9%)
Decreased appetite (8%)
Anxiety (7%)
Dry mouth (4%)
Diarrhea (5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Other AEs: Headache, Nausea...
Other AEs:
Headache (7%)
Nausea (7%)
Decreased appetite (2%)
Anxiety (2%)
Dry mouth (2%)
Diarrhea (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Other AEs: Headache, Nausea...
Other AEs:
Headache (9%)
Nausea (5%)
Decreased appetite (7%)
Anxiety (3%)
Dry mouth (3%)
Diarrhea (4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Other AEs: Decreased appetite, Anxiety...
Other AEs:
Decreased appetite (6%)
Anxiety (4%)
Irritability (3%)
Dizziness (2%)
Palpitations (3%)
Nausea (8%)
Diarrhea (4%)
Abdominal pain (3%)
Dry mouth (3%)
Feeling jittery (3%)
Chest discomfort (2%)
Hyperhidrosis (2%)
Bruxism (<2%)
Restlessness (<2%)
Disturbance in attention (<2%)
Tremor (<2%)
Cough (<2%)
Dyspnea (<2%)
Constipation (<2%)
Vomiting (<2%)
Weight decreased (<2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 396
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 396
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Other AEs: Blood pressure systolic increased, Blood pressure diastolic increased...
Other AEs:
Blood pressure systolic increased
Blood pressure diastolic increased
Heart rate increased
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Other AEs: Insomnia, Headache...
Other AEs:
Insomnia (grade 1, 21.9%)
Headache (grade 1, 15.6%)
Hypervigilance (grade 1, 9.4%)
Decreased appetite (grade 1, 9.4%)
Nausea (grade 1, 9.4%)
Insomnia (grade 1, 21.9%)
Headache (grade 1, 12.5%)
Hypervigilance (grade 1, 12.5%)
Decreased appetite (grade 1, 9.4%)
Nausea (grade 1, 6.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Disc. AE: Blood pressure increased, Nervousness...
Other AEs: Hypervigilance, Elevated mood...
AEs leading to
discontinuation/dose reduction:
Blood pressure increased (grade 1, 2.4%)
Nervousness (grade 1, 2.4%)
Other AEs:
Hypervigilance (42.9%)
Elevated mood (23.8%)
Dry mouth (21.4%)
Nausea (21.4%)
Feeling of relaxation (19%)
Decreased appetite (19%)
Hyperhidrosis (19%)
Insomnia (16.7%)
Headache (14.3%)
Restlessness (14.3%)
Palpitations (11.9%)
Paresthesia (7.1%)
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
150 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
unhealthy
n = 417
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Sex: M+F
Population Size: 417
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
Disc. AE: Blood pressure increased, Hypertension...
AEs leading to
discontinuation/dose reduction:
Blood pressure increased (0.48%)
Hypertension (0.24%)
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
AEs

AEs

AESignificanceDosePopulation
Headache 16%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Palpitations 2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Constipation 3%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Dry mouth 4%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Insomnia 5%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Anxiety 6%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Nausea 7%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Decreased appetite 9%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Agitation <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Bruxism <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Chest discomfort <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Chest pain <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Cough <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Feeling jittery <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Hyperhidrosis <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Irritability <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Thirst <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Weight decreased <2%
112.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 112.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 112.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 161
Health Status: unhealthy
Condition: narcolepsy
Age Group: 18 to 75 years
Sex: M+F
Population Size: 161
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Anxiety 0.5%
Disc. AE
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Palpitations 0.5%
Disc. AE
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Restlessness 0.5%
Disc. AE
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Headache 13%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Dry mouth 4%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Diarrhea 5%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Anxiety 7%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Decreased appetite 8%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Nausea 9%
150 mg 1 times / day steady, oral (mean)
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 218
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Anxiety 2%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Decreased appetite 2%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Diarrhea 2%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Dry mouth 2%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Headache 7%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Nausea 7%
37.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 58
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Anxiety 3%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Dry mouth 3%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Diarrhea 4%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Nausea 5%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Decreased appetite 7%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Headache 9%
75 mg 1 times / day steady, oral (mean)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: steady
Dose: 75 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 120
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 120
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Chest discomfort 2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Dizziness 2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Hyperhidrosis 2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Abdominal pain 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Dry mouth 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Feeling jittery 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Irritability 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Palpitations 3%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Anxiety 4%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Diarrhea 4%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Decreased appetite 6%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Nausea 8%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Bruxism <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Constipation <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Cough <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Disturbance in attention <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Dyspnea <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Restlessness <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Tremor <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Vomiting <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Weight decreased <2%
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 235
Health Status: unhealthy
Condition: obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 235
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Blood pressure diastolic increased
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 396
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 396
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Blood pressure systolic increased
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 396
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 396
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Heart rate increased
87.5 mg 1 times / day steady, oral (mean)
Recommended
Dose: 87.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 87.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
unhealthy, 18 to 75 years
n = 396
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Age Group: 18 to 75 years
Sex: M+F
Population Size: 396
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
Headache grade 1, 12.5%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Hypervigilance grade 1, 12.5%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Headache grade 1, 15.6%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Insomnia grade 1, 21.9%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Insomnia grade 1, 21.9%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Nausea grade 1, 6.3%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Decreased appetite grade 1, 9.4%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Decreased appetite grade 1, 9.4%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Hypervigilance grade 1, 9.4%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Nausea grade 1, 9.4%
300 mg 1 times / day single, oral
Studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: single
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
healthy, 19 to 54 years
n = 32
Health Status: healthy
Age Group: 19 to 54 years
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/30598342/
Palpitations 11.9%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Headache 14.3%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Restlessness 14.3%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Insomnia 16.7%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Decreased appetite 19%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Feeling of relaxation 19%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Hyperhidrosis 19%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Dry mouth 21.4%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Nausea 21.4%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Elevated mood 23.8%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Hypervigilance 42.9%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Paresthesia 7.1%
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Blood pressure increased grade 1, 2.4%
Disc. AE
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Nervousness grade 1, 2.4%
Disc. AE
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
healthy, mean age 29.3 years
n = 42
Health Status: healthy
Age Group: mean age 29.3 years
Sex: M
Population Size: 42
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/30269642/
Hypertension 0.24%
Disc. AE
150 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
unhealthy
n = 417
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Sex: M+F
Population Size: 417
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
Blood pressure increased 0.48%
Disc. AE
150 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
unhealthy
n = 417
Health Status: unhealthy
Condition: narcolepsy | obstructive sleep apnea
Sex: M+F
Population Size: 417
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1604
inhibitor
1702
inhibitor
1475

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1383

CYP2A6
627

CYP2B6
717

CYP2C8
818

CYP2C19
1325

CYP2E1
790

CYP3A4/5
241

UGT
31

P-gp
1330

BCRP
643

OATP1B1
733

OATP1B3
657

OAT1
554

OAT3
588

OCT1
480

MATE2
251

OCTN1
30

OCTN2
66

OCT2
594

MATE1
290

UGT1A
3

UGT2B7
141
P-gp
1400

BCRP
515

OATP1B1
370

OATP1B3
319

OAT1
294

OAT3
305
CYP1A2
637

CYP2B6
501

CYP3A4/5
108

UGT
27
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BCRP
713
 no
CYP1A2
1532
 no
CYP1A2
1532
 no
CYP2A6
659
 no
CYP2B6
884
 no
CYP2B6
884
 no
CYP2C19
1392
 no
CYP2C8
865
 no
CYP2C9
1648
 no
CYP2E1
871
 no
CYP3A4/5
293
 no
CYP3A4/5
293
 no
MATE2
251
 no
OAT1
558
 no
OAT3
590
 no
OATP1B1
748
 no
OATP1B3
666
 no
OCT1
495
 no
OCTN1
30
 no
OCTN2
71
 no
P-gp
1514
 no
UGT
54
 no
UGT
54
 no
UGT1A
5
 no
UGT2B7
152
 no
OCT2
595
 weak [IC50 146 uM]
MATE1
292
 weak [IC50 211 uM]
CYP2D6
1738
 weak [IC50 360 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
515
 no
OAT1
294
 no
OAT3
305
 no
OATP1B1
370
 no
OATP1B3
319
 no
P-gp
1400
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1507
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P01C3BA
A2B Chem
AW42982
AA Blocks
AA01C2RU
AChemBlock
Q69522
Chem Scene
CS-0031486
http://www.chemscene.com/178429-62-4.html
ChemShuttle
139041
Chemspace
CSSB00041015464
https://chem-space.com/CSSB00041015464
Enamine
BBV-44122269
Enamine
BBV-77772338
Enamine
EN300-253107
Hairui
R2CQ017
KeyOrganics
CS-2577
MedChem Express
HY-109043
https://www.medchemexpress.com/solriamfetol.html
MolPort
MolPort-039-241-646
MolPort
MolPort-046-793-373
MolPort
MolPort-047-156-022
Molnova
M12688
MuseChem
I009552
Smolecule
S543563
http://www.smolecule.com/products/s543563
Smolecule
S727641
https://www.smolecule.com/products/s727641
THE BioTek
bt-284158
https://www.thebiotek.com/product/inhibitors/bt-284158
THE BioTek
bt-386716
https://www.thebiotek.com/product/others/bt-386716
Toronto Research Chemicals
S676775
ZINC
ZINC000034278783
http://zinc15.docking.org/substances/ZINC000034278783
eMolecules
222563444
eMolecules
303230315
eMolecules
67911099
mcule
MCULE-3233675360
PubMed

PubMed

TitleDatePubMed
Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
2015 Sep
Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
2016 Jul 1
New developments in the management of narcolepsy.
2017

Sample Use Guides

In Vivo Use Guide
The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.
Route of Administration: Oral
In Vitro Use Guide
Solriamfetol binds to the dopamine transporter and norepinephrine transporter with low affinity (Ki=14.2 uM and 3.7 uM, respectively), and inhibits the reuptake of dopamine and norepinephrine with low potency (IC50 =2.9 uM and 4.4 uM, respectively). Solriamfetol has no appreciable binding affinity for the serotonin transporter (Ki=81.5 uM) and does not inhibit serotonin reuptake (IC50 > 100 uM).
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:36:59 UTC 2021
Edited
by admin
on Sat Jun 26 02:36:59 UTC 2021
Record UNII
939U7C91AI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOLRIAMFETOL
USAN   INN  
Official Name English
(2R)-2-AMINO-3-PHENYLPROPYL CARBAMATE
Systematic Name English
SOLRIAMFETOL [ORANGE BOOK]
Common Name English
YKP-10A
Code English
R-228060
Code English
SOLRIAMFETOL [WHO-DD]
Common Name English
SUNOSI
Brand Name English
BENZENEPROPANOL, .BETA.-AMINO-, CARBAMATE (ESTER), (R)-
Systematic Name English
BENZENEPROPANOL, .BETA.-AMINO-, 1-CARBAMATE, (.BETA.R)-
Systematic Name English
JZP-110
Code English
SOLRIAMFETOL [INN]
Common Name English
ADX-N-05
Code English
SKL-N-05
Code English
SOLRIAMFETOL [USAN]
Common Name English
SOLRIAMFETOL [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78272
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
Code System Code Type Description
INN
10117
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
DRUG CENTRAL
5325
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
RXCUI
2121751
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
MERCK INDEX
M12132
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
FDA UNII
939U7C91AI
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
CAS
178429-62-4
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
PUBCHEM
10130337
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
DRUG BANK
DB14754
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
NCI_THESAURUS
C152389
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
LACTMED
Solriamfetol
Created by admin on Sat Jun 26 02:36:59 UTC 2021 , Edited by admin on Sat Jun 26 02:36:59 UTC 2021
PRIMARY
Related Record Type Details
Structure of SOLRIAMFETOL HYDROCHLORIDE
SALT/SOLVATE -> PARENT
OCT-2
TRANSPORTER -> INHIBITOR
WEAK
IC50
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
WEAK
IC50
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of SOLRIAMFETOL
EXCRETED UNCHANGED
Approximately 95% of the dose was recovered in urine as unchanged solriamfetol, 1% or less of the administered dose was recovered in urine as the minor inactive metabolite N-acetyl solriamfetol.
URINE
SODIUM-DEPENDENT DOPAMINE TRANSPORTER
TARGET -> INHIBITOR
Ki
SODIUM-DEPENDENT NORADRENALINE TRANSPORTER
TARGET -> INHIBITOR
Ki
Related Record Type Details
Structure of N-ACETYL SOLRIAMFETOL
METABOLITE INACTIVE -> PARENT
Structure of PHENYLALANINOL, D-
METABOLITE -> PARENT
Related Record Type Details
Structure of SOLRIAMFETOL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
Tmax PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966